Abstract: Described are effervescent dissolvable solid structures having fibers formed from a composition comprising surfactant and water soluble polymeric structurant, having a total dissolvable solid structure density of from about 0.100 g/cm3 to about 0.380 g/cm3, having a surfactant dose of from about 0.5 to about 2.0 g, and a surfactant density of from about 0.1 g/cm3 to about 0.3 g/cm3. Also described are processes for manufacturing the Dissolvable Solid Structure.

Abstract: The present invention relates to formulae for infants comprising large lipid globules and/or lipid globules with a coating of phospholipids for rendering the growth trajectory or body development during the first year of life more similar to that observed for human milk fed infants.

Abstract: The present invention relates to a method for constructing a whitlockite coating on a surface of a calcium phosphate-based bioceramic substrate and a resulting coating, wherein the preparation method includes the following steps of: preparing pure calcium phosphate-based bioceramic powder firstly, then pre-firing, shaping and calcining the pure calcium phosphate-based bioceramic powder to obtain a calcium phosphate-based bioceramic substrate, placing the substrate in a solution containing Mg2+, then transferring the substrate to a high-temperature high-pressure reaction kettle for a hydrothermal reaction, and then cleaning and drying the sample to obtain a whitlockite coating.

Abstract: The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.

Abstract: The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.

Abstract: It is an object of the present invention to suppress agglutination of ultrafine cellulose fibers, while using the ultrafine cellulose fibers as a thickener in a cosmetic product formulation, so as to provide a uniform cosmetic. The present invention provides a cosmetic comprising the following components (A) and (B): (A) ultrafine cellulose fibers having a fiber width of 1000 nm or less; and (B) a water-soluble polymer.

Abstract: The present invention relates to an antibacterial co-polymer comprising a water soluble backbone polymer having in at least one end a dendritic or hyperbranched polymer of generation 1 to 6 wherein at least one functional group comprising a carboxylic amine has been covalently attached to the periphery of the dendritic or hyperbranched polymer. The present invention also relates to said anti-bacterial co-polymer when said co-polymer has been cross-linked with a cross-linking agent and to uses of the cross-linked co-polymer in a hydrogel for the treatment or prevention of bacterial infections, particularly in surgical site infections (SSIs).

Abstract: The present invention relates to a fibrous nerve conduit for promoting nerve regeneration, comprising a channel, the channel having diameter controllable ends, the channel is adjustable to suturing to a proximal and distal end of a severed nerve, the conduit further comprises a PCL (MW:70KDa) with concentration of 10-15% and PLGA (MW:50KDa,50:50) with concentration of 10-18%.

Abstract: A preparation method and an application of a composite scaffold for directionally guiding regeneration of optic nerve axons. A major component of the composite scaffold is prepared from one or more degradable biomedical materials combined according to different ratios by a gradient freezing method. To increase a mechanical property of the scaffold or prolong in-vivo degradation time, the scaffold may be cross-linked by a biological cross-linker. After a gelatin is added, the prepared composite scaffold exhibits excellent mechanical properties and biocompatibility. A problem of solubility differences of the gelatin A produced during gradient freezing can be regulated by sodium alginate, thereby facilitating regular directional pipeline morphology of the scaffold.

Abstract: Compositions and methods are provided for mitigating the effects of alcohol by delaying alcohol absorption and/or reducing blood alcohol concentration, and/or for delaying gastric emptying.

Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Abstract: The present disclosure provides a method for treating clinical or pre-clinical skin damage in a skin field of a subject, wherein the skin field has been allocated a skin cancerization field index (SCFI) score of at least 1 as determined by a process comprising the steps of: (i) assessing the number of keratoses in the skin field; (ii) assessing the thickness of the thickest keratosis in the skin field; and (iii) assessing the proportion of the field affected by clinical or subclinical skin damage. Based on the assessments made in (i), (ii) and (iii) the subject is optionally treated by at least one of (a) freezing one or more lesions, (b) shaving, curetting or surgically removing one or more lesions, (c) applying a topical treatment for actinic keratosis, basal cell carcinoma or squamous cell carcinoma, and (d) radiation therapy.

Abstract: This invention relates to a membrane and method for the preservation of agricultural produce. According to a first aspect of the invention there is provided a membrane for the preservation of agricultural produce comprising first and second outer polymeric layers, at least one of the outer polymeric layers being impregnated with a hydrophilic agent, and an inner layer dispersed in between the outer layers, the inner layer consisting of a polymer being impregnated with a carrier for incorporation of an antimicrobial volatile into the inner layer, the inner layer further including an absorptive agent, wherein in use, the membrane is placed proximate to agricultural produce to be preserved.

Abstract: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.

Abstract: This disclosure provides compositions and methods for delivery of a polynucleotide to an organism. More specifically, this disclosure relates to compositions including a mixture of a polynucleotide and a cationic polysaccharide, and methods of providing such compositions to an organism, such as a pest (e.g., an insect, a nematode, a mollusk).

Abstract: Gastric retentive devices and systems including a gastric retentive element including at least one expandable compartment and a dosage form element including at least one active agent are provided. The devices and systems, as well as kits thereof are used in a method for in-situ release and delivery of the at least one active agent.

Abstract: A composition intended to be employed for therapeutic purposes incorporates a nicotinic compound, a sugar substitute, and a sugar alcohol syrup. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and as a nicotine replacement therapy.

Abstract: Mineral, cosmetic, pharmaceutical, agricultural, nutraceutical, and other compositions are produced using a mineral composition containing minimal concentrations of cadmium, lead, arsenic, and mercury and containing relatively high concentrations of micro and macro mineral elements, of rare earth elements, of calcium, and of silica. The mineral concentrations are produced by processing naturally occurring clay soil to concentrate mineral elements naturally occurring in the soil.

Abstract: Described herein is an array of wet wipe packages displayed via a merchandise display system. The array of wet wipe packages includes a first package, a second package, and a third package. The first package includes a first wet wipe having a first coform nonwoven material and a first lotion which is devoid of perfume. The second package includes a second wet wipe having a second coform nonwoven material and a second lotion which includes a perfume. The third package includes a third wet wipe having a third coform nonwoven material and a third lotion. The third lotion is different than the first lotion and the second lotion. The first coform nonwoven material, the second coform nonwoven material, and/or the third coform nonwoven material has from about 14.5% to about 45% cotton.